Cargill has announced that, Cargill Alking Bioengineering (Hubei) Co., Ltd., a joint venture between Cargill and Alking Bioengineering, is nearing completion of a new facility for the production of arachidonic acid-rich oil (ARA), a product used primarily in infant formula. The facility, which will begin production in early 2010, is located near the current facility in Wuhan, China.
"The completion of this new facility will give Cargill the capacity to provide our global infant formula customers with ARA for years to come," said Marcelo Montero, president, Cargill Health and Nutrition. "The production complex was designed to meet the strict requirements of the international infant formula industry and will give us the flexibility to serve our customers with additional, high-quality capacity as well as the potential for new product lines."
Cargill and Cargill Alking Bioengineering have been serving China and select international infant formula markets with high quality arachidonic acid since 2004.
Cargill is an international provider of food, agricultural and risk management products and services. With 159,000 employees in 68 countries, the company is committed to using its knowledge and experience to collaborate with customers to help them succeed. For more information, visit http://www.cargill.com.